Sjögren’s Syndrome News

Dry eye in Sjögren’s syndrome remains “underdiagnosed and undertreated,” and often not fully understood, according to Sjögren Europe, which is gearing up for World Sjögren’s Day on July 23 with a campaign aimed at raising awareness online.

SAN FRANCISCO — New real-world data demonstrate treatment with selexipag improved outcomes in patients with pulmonary arterial hypertension associated with connective tissue disease.

DESTIN, Fla. — Although not currently curable, the symptoms of Sjögren’s syndrome, like dry eyes and dry mouth, can be effectively managed using a variety of therapies, said a speaker said at the Congress of Clinical Rheumatology East 2022 meeting.

DESTIN, Fla. — Myriad symptoms and three different sets of classification criteria make Sjögren's syndrome a challenging diagnosis, according to a presenter at the Congress of Clinical Rheumatology East.

The Sjögren’s Tool for Assessing Response, or STAR, a candidate composite efficacy endpoint for clinical trials, includes all disease features and has demonstrated sensitivity to change, according to researchers.

Impacting roughly 1 million to 4 million Americans, Sjögren’s syndrome is estimated to be one of the most common autoimmune diseases in the United States, according to the Sjögren’s Foundation.

Rilzabrutinib induced rapid and durable clinical activity in previously treated patients with immune thrombocytopenia, according to results of a phase 1/phase 2 clinical trial published in The New England Journal of Medicine.

March is Autoimmune Awareness Month, and rheumatology organizations have been using their reach and influence on social media sites to spread the word and help patients with autoimmune diseases find community.

Nintedanib slows the rate of forced vital capacity decline in patients with fibrosing autoimmune disease-related interstitial lung disease, with adverse events manageable for most, according to data published in Arthritis & Rheumatology.

One out of three registered randomized controlled trials on connective tissue diseases are never completed or published, representing a “waste of energy or resources” that may skew meta-analyses, according to researchers.